Bli medlem
Bli medlem

Du är här



Technological Advances Are Making Hair Loss from Chemotherapy a Thing
of the Past

Lund, Sweden and Dallas, TX - December 8, 2016-One year to the date of
receiving FDA Clearance for the DigniCap® scalp cooling system to
prevent hair loss in women with breast cancer, Dignitana AB and
Dignitana, Inc., are proud to announce that the device will soon be
available in 53 medical centers across 17 U.S. states, with demand
continuing to grow.

The DigniCap® system is the first and only scalp cooling device to
receive clearance after completing rigorous U.S. FDA clinical trials,
where seven out of ten patients with early-stage breast cancer kept
at least 50% of their hair.

As 2017 approaches, clinical interest in DigniCap® continues to
accelerate, and Dignitana will demonstrate new technological advances
at its booth at the San Antonio Breast Cancer Symposium
( (SABCS), where it will also
offer a scalp cooling poster presentation on December 9th. Product
enhancements developed in this first year include comfort and
temperature modifications and an exclusive partnership with Denver
based Boa® Technology
( to customize and
create a more precise outer cap fit using the award-winning Boa®
Closure System. Visit Dignitana at SABCS in booth 435.

"This is an incredibly exciting period of growth for us here in the
U.S.," said William Cronin, Chief Executive Officer of Dignitana,
Inc., "Oncologists and clinicians in medical centers across the
country recognize the benefits that scalp cooling can provide their
patients. We are proud to be able to offer the only FDA cleared
option for reducing chemo-induced hair loss, and we are especially
pleased to be partnering with innovators like Boa who can bring their
exciting technology to improve our product as we continue to learn
and grow."

The DigniCap® scalp cooling system features a patented tight-fitting
silicone cooling cap that is placed directly on the head, and an
outer neoprene cap that insulates and secures the silicone cap. The
cooling cap is connected to a cooling and control unit with touch
screen prompts. A liquid coolant circulates throughout the silicone
cap, delivering consistent and controlled cooling to all areas of the
scalp. The cap is fitted to the head, and the temperature of the
scalp is lowered, resulting in vasoconstriction with reduced delivery
of chemotherapy to the scalp, as well as reduced cellular uptake of
drugs due to decreased intra follicular metabolic rate. These factors
together reduce the risk of chemotherapy-induced hair loss.

About Dignitana AB (publ)

Dignitana is a Swedish public company, based in Lund, and manufacturer
of the medical cooling device DigniCap®. Dignitana AB is listed on
the OMX Nasdaq First North stock exchange and has appointed Erik
Penser Bank as Certified Advisor. Headquartered in Dallas, Texas,
Dignitana, Inc. is the U.S. subsidiary of Dignitana AB. For more
information visit

For more information:

For Dignitana, Inc.: For Dignitana AB:
Caren Browning Semmy Rülf
King + Company Chairman of the Board
00 1 212 561-7464 0046 (0)709 312730 s



Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.